Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Valeant Pharmaceuticals Intl (VRX) Share Price
Headlines about Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Valeant Pharmaceuticals Intl earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.8442633746452 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Investors Recap on Valeant Pharmaceuticals International, Inc. (VRX) with Unusual Volume – Wall Street Morning (wallstreetmorning.com)
- Conquer Concerns on Short-Term Commitments: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) – Stock News Stop (stockmarketstop.com)
- Valeant Pharmaceuticals International, Inc., (NYSE: VRX) – Active Mover – Stock Watch (stocksnewstimes.com)
- Hot Stock’s Watch List – Valeant Pharmaceuticals International, Inc. (NYSE: VRX) – Alpha Beta Stock (alphabetastock.com)
- Valeant Pharmaceuticals Intl (VRX) Raised to “Strong-Buy” at Vetr (americanbankingnews.com)
A number of research analysts have issued reports on the company. Cantor Fitzgerald set a $25.00 target price on Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Co reaffirmed an “underperform” rating and set a $8.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Saturday, September 30th. Vetr raised Valeant Pharmaceuticals Intl from a “strong sell” rating to a “sell” rating and set a $12.46 price objective for the company in a research report on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “sell” rating and set a $14.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, September 17th. Finally, HC Wainwright reaffirmed a “hold” rating and set a $17.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 18th. Six investment analysts have rated the stock with a sell rating, ten have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $17.83.
Shares of Valeant Pharmaceuticals Intl (NYSE VRX) traded up $0.10 during midday trading on Tuesday, reaching $21.65. The company had a trading volume of 10,701,437 shares, compared to its average volume of 18,313,611. Valeant Pharmaceuticals Intl has a 1 year low of $8.31 and a 1 year high of $22.81. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. The firm has a market capitalization of $7,512.15, a PE ratio of 5.55, a PEG ratio of 0.59 and a beta of -0.22.
In related news, Director John Paulson purchased 344,216 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the transaction, the director now owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.87% of the company’s stock.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.